The Clinical Core is critical to the function of the Indiana Alzheimer Disease Center. Its role is to recruit, clinically characterize and longitudinally follow patients with MCI, AD, non-AD and mixed dementia and healthy controls. A major emphasis is to identify and clinically characterize families with AD and new genetically distinct non-AD dementias with emphasis on identifying patients in the earliest stages of illness. These patients will be further characterized by the Neuropathology Core. In conjunction with the Neuropathology Core, the Clinical Core will obtain and bank biology materials (DNA, plasma and CSF) from participating subjects to support studies pertaining to dementias. Patients from the Clinical Core will be offered as appropriate participation in ADNI, LOAD, investigational drug trials and other local and multicenter research studies. We will continue to support the NCRAD. We will continue our educational efforts in the general elderly as well as African American communities to communicate and facilitate autopsy. After autopsy, clinical-genetic-neuropathological correlation will increase the understanding of AD and non-AD dementias and support further investigations of biochemical abnormalities and/or underlying disease mechanisms.
It is estimated that as many as 5 million Americans have AD. The Indiana Alzheimer Disease Center provides an environment and resources directed towards fostering and coordinating research and educational activities on AD and other dementing illnesses.
|Li, Huang; Fang, Shiaofen; Contreras, Joey A et al. (2017) Brain explorer for connectomic analysis. Brain Inform 4:253-269|
|Yao, Xiaohui; Yan, Jingwen; Ginda, Michael et al. (2017) Mapping longitudinal scientific progress, collaboration and impact of the Alzheimer's disease neuroimaging initiative. PLoS One 12:e0186095|
|Sano, Mary; Zhu, Carolyn W; Grossman, Hillel et al. (2017) Longitudinal Cognitive Profiles in Diabetes: Results From the National Alzheimer's Coordinating Center's Uniform Data. J Am Geriatr Soc 65:2198-2204|
|Sokolow, Sophie; Li, Xiaohui; Chen, Lucia et al. (2017) Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis 56:229-237|
|Tripodis, Yorghos; Alosco, Michael L; Zirogiannis, Nikolaos et al. (2017) The Effect of Traumatic Brain Injury History with Loss of Consciousness on Rate of Cognitive Decline Among Older Adults with Normal Cognition and Alzheimer's Disease Dementia. J Alzheimers Dis 59:251-263|
|Jefferson-George, Kyra S; Wolk, David A; Lee, Edward B et al. (2017) Cognitive decline associated with pathological burden in primary age-related tauopathy. Alzheimers Dement 13:1048-1053|
|Brenowitz, Willa D; Hubbard, Rebecca A; Keene, C Dirk et al. (2017) Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement 13:654-662|
|Brosch, Jared R; Farlow, Martin R; Risacher, Shannon L et al. (2017) Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials. Neurotherapeutics 14:62-68|
|Jutkowitz, Eric; Kane, Robert L; Gaugler, Joseph E et al. (2017) Societal and Family Lifetime Cost of Dementia: Implications for Policy. J Am Geriatr Soc 65:2169-2175|
|Garringer, Holly J; Sammeta, Neeraja; Oblak, Adrian et al. (2017) Amyloid and intracellular accumulation of BRI2. Neurobiol Aging 52:90-97|
Showing the most recent 10 out of 531 publications